Allaforte, 50 mg 10 pcs.

The active ingredient of the drug is bromine hydrogenate salt of lappaconitin alkaloid with accompanying alkaloids, derived from white bean hogweed herb or rhizomes and roots of white bean hogweed – Aconitum leucostomum Worosch, or from rhizomes with roots of northern wolfberry (high wolfberry) – Aconitum septentrionale Koelle (A. excelsum Reichenb.), family Ranunculaceae, or from technical alkaloids sum of the buttercup family.

Indications

Supraventricular and ventricular extrasystole, paroxysmal form of atrial fibrillation and flutter, paroxysmal supraventricular tachycardia, including in Wolff-Parkinson-White syndrome, paroxysmal ventricular tachycardia (in the absence of organic changes in the myocardium).

Pharmacological effect

The active substance of the drug is the hydrobromide salt of the alkaloid lappaconitine with accompanying alkaloids, obtained from the grass of the white-mouthed wrestler or from the rhizomes and roots of the white-mouthed wrestler – Aconitum leucostomum Worosch., or from the rhizomes with roots of the northern wrestler (high wrestler) – Aconitum septentrionale Koelle (A. excelsum Reichenb.), family Ranunculaceae – Ranunculaceae, or from the technical sum of alkaloids of the Ranunculaceae family.

Active ingredient

Lappaconitine hydrobromide

Composition

For 1 tablet:

Pregnancy

Animal studies have shown that lappaconitine hydrobromide in doses of 1-5 mg/kg does not have teratogenic or embryotoxic effects.

Contraindications

Hypersensitivity to the components of the drug, sinoatrial block, AV block II and III degrees (without an artificial pacemaker), cardiogenic shock, right bundle branch block combined with blockade of one of the branches of the left leg, severe arterial hypotension (systolic blood pressure less than 90 mm Hg), chronic heart failure III-IV functional class according to the NYHA classification, severe myocardial hypertrophy left ventricle (≥1.4 cm), the presence of post-infarction cardiosclerosis, acute coronary syndrome, Brugada syndrome, arrhythmogenic cardiomyopathy (dysplasia) of the right ventricle, severe liver and/or kidney dysfunction, age under 18 years, lactose intolerance, lactase deficiency or glucose-galactose malabsorption, long or short QT interval syndrome, heart defects, arrhythmogenic effect of any antiarrhythmic drug in history, pregnancy, breastfeeding, alcohol abuse, AV block of the first degree with prolongation of the PQ interval more than 200 ms, dilated cardiomyopathy, restrictive cardiomyopathy, myocarditis, lack of antiarrhythmic effect during treatment with Allapinin in the anamnesis.

Side Effects

According to the World Health Organization, adverse effects are classified according to their frequency as follows: very common (≥10% of prescriptions); often (≥1% and <10%); uncommon (≥0.1% and <1%); rare (≥0.01% and <0.1%); very rare (<0.01%); frequency unknown (insufficient data to estimate the frequency of development).

Interaction

Inducers of microsomal liver enzymes do not affect the effectiveness of lappaconitine hydrobromide.

Overdose

The drug has a small therapeutic breadth, so severe intoxication can easily occur (especially with simultaneous use of other antiarrhythmic drugs).

Recommendations for use

The drug should be taken under the supervision of a doctor. Orally, after eating, swallow the tablet whole and drink a small amount of water at room temperature. Tablets are strictly prohibited from breaking, crushing or chewing!

Storage conditions

In a place protected from light, at a temperature not exceeding 25 ° C.

Shelf life

3 years

Manufacturer

Pharmcenter VILAR JSC, Russia